Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors
Jessica Lee, Smruthy Sivakumar, Alexa B. Schrock, et al.
npj Precision Oncology (2022) Vol. 6, Iss. 1
Open Access | Times Cited: 73

Showing 1-25 of 73 citing articles:

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
Marwan Fakih, Lisa Salvatore, Taito Esaki, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 23, pp. 2125-2139
Closed Access | Times Cited: 157
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation
Adrian G. Sacher, Patricia LoRusso, Manish R. Patel, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 8, pp. 710-721
Open Access | Times Cited: 151
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
Matthew Holderfield, Bianca J. Lee, Jingjing Jiang, et al.
Nature (2024) Vol. 629, Iss. 8013, pp. 919-926
Open Access | Times Cited: 90
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Jayesh Desai, Guzmán Alonso, Se Hyun Kim, et al.
Nature Medicine (2023) Vol. 30, Iss. 1, pp. 271-278
Open Access | Times Cited: 53
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
Abdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 38
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Julien Dilly, Megan T. Hoffman, Laleh Abbassi, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2135-2161
Closed Access | Times Cited: 36
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial
Yasutoshi Kuboki, Marwan Fakih, John H. Strickler, et al.
Nature Medicine (2024) Vol. 30, Iss. 1, pp. 265-270
Open Access | Times Cited: 34
Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver
Javier Ros, Caterina Vaghi, Iosune Baraibar, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3304-3304
Open Access | Times Cited: 15
KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma
Carter Norton, Matthew Shaw, Zachary Rubnitz, et al.
JAMA Network Open (2025) Vol. 8, Iss. 1, pp. e2453588-e2453588
Open Access | Times Cited: 2
Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies
Anna Linehan, Mary O’Reilly, Ray McDermott, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 13
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, et al.
Cancer Discovery (2024) Vol. 14, Iss. 8, pp. 1440-1456
Open Access | Times Cited: 13
Digestive cancers: mechanisms, therapeutics and management
Tianzuo Zhan, Johannes Betge, Nadine Schulte, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Dynamic Multilevel Regulation of EGFR, KRAS, and MYC Oncogenes: Driving Cancer Cell Proliferation Through (Epi)Genetic and Post-Transcriptional/Translational Pathways
Mário Šereš, Katarina Spacayova, Zdena Sulová, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 248-248
Open Access | Times Cited: 1
Genomic characterization of thymic epithelial tumors in a real-world dataset
Ken Kurokawa, Takehito Shukuya, R.A. Greenstein, et al.
ESMO Open (2023) Vol. 8, Iss. 5, pp. 101627-101627
Open Access | Times Cited: 16
Deep-Learning Model for Tumor-Type Prediction Using Targeted Clinical Genomic Sequencing Data
Madison Darmofal, Shalabh Suman, Gurnit Atwal, et al.
Cancer Discovery (2024) Vol. 14, Iss. 6, pp. 1064-1081
Open Access | Times Cited: 7
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos, et al.
Molecular Cancer Therapeutics (2024) Vol. 23, Iss. 10, pp. 1418-1430
Open Access | Times Cited: 6
KRAS inhibitors: resistance drivers and combinatorial strategies
Tamara Isermann, Christine Sers, Channing J. Der, et al.
Trends in cancer (2024)
Open Access | Times Cited: 6
The prognostic and immune significance of C15orf48 in pan-cancer and its relationship with proliferation and apoptosis of thyroid carcinoma
Chaolin Li, Yan Tang, Qin Li, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 13
Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC
Danielle Brazel, Misako Nagasaka
Targeted Oncology (2024) Vol. 19, Iss. 3, pp. 297-301
Open Access | Times Cited: 5
Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors
Luciana Alexandra Pavelescu, Robert Mihai Enache, Oana Alexandra Roşu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 17, pp. 9659-9659
Open Access | Times Cited: 5
Identification of novel KRASG12D neoantigen specific TCRs and a strategy to eliminate off-target recognition
Xiaojian Han, Xiaxia Han, Yanan Hao, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Driver mutation detected in cerebrospinal fluid despite negative liquid biopsy results
Kei Kunimasa, Daisuke Aohara, Kazumi Nishino
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Treatment options for KRAS G12C mutated metastatic colorectal cancer
Marián Liberko
Onkologie (2025) Vol. 19, Iss. 1, pp. 33-36
Closed Access
Network pharmacology and AI in cancer research uncovering biomarkers and therapeutic targets for RALGDS mutations
S. Mohammed Zaidh, Hariharan Thirumalai Vengateswaran, Mohammad Habeeb, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program
Francesco Passiglia, Maria Lucia Reale, Giuseppe Lo Russo, et al.
Lung Cancer (2023) Vol. 187, pp. 107444-107444
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top